Edwards Announces $1.2 Billion Acquisition of Two Structural Heart Companies:JenaValve TechnologyAndEndotronix。These are Edwards' four deals in a month. Previously, it acquired mitral valve company Innoval for $300 million. Edwards also reached a series of agreements with Affluent Medical to obtain the license and development rights for Kalios’ adjustable mitral annuloplasty ring and mitral valve technology.
"These acquisitions expand our opportunity to address the unmet needs of patients worldwide with aortic regurgitation and heart failure. We are excited to enter these structural heart therapy areas with innovative, world-class science and clinical evidence, bringing life-saving technologies to patients around the globe."---Bernard Zovighian, CEO of Edwards LifesciencesJenaValve TechnologyIs a company dedicated to solving unmet clinical needsSatisfactory aortic regurgitation (AR).Currently in the worldMainstream valve companies' products can only address aortic stenosis (AS), including Edwards.The Sapie series and its competitor Medtronic's Evolut series. In recent years, Medtronic has launched wave after wave of attacks on Edwards in the TAVR field, whether it is...Head-to-Head Study of the Evolut Series with SAVR, Still in the Small Annulus FieldEvolut Series andSapie Series Head-to-Head. Medtronic's data appears to be better than Edwards', putting Edwards in a very passive position in the market.And this acquisitionJenaValve Technology, undoubtedly widening the gap between Edwards and Medtronic, allowing Edwards to continue maintaining its leading position in TAVR.According to the description in the "Chinese Expert Consensus on Transcatheter Aortic Valve Replacement (2020)":Compared with Western countries, there are some differences in TAVR candidate patients in China: a higher proportion of bicuspid aortic valve (BAV), a higher degree of aortic valve calcification, more aortic regurgitation (AR) than aortic stenosis (AS), a higher proportion of rheumatic etiology, and narrower femoral artery diameter.。Although the proportion of AR patients overseas is relatively smaller compared to that in China, it still represents a large population.EndotronixIs an innovative company dedicated to remote heart failure monitoring., its productsCordellaReceived FDA approval for marketing last month (For the treatment of patients with NYHA Class III heart failure), this is the firstPA Pressure Guidance Platform: Comprehensive patient management provided by daily PA pressure and vital signs monitoring at home to guide treatment management and improve patient outcomes.RemoteIn the field of heart failure monitoring, Edwards' biggest competitor is Abbott (an old rival of Edwards).Hand). Abbott's productsCardioMEMS HF can significantly reduce the mortality rate in HFrEF patients within two years (by 25%).. AndCordella also did not give in, and studies have shown that it is able toSignificantly reduce patient hospitalization rates, significantly improve quality of life, and increase patient physical activity.Improvement in NYHA Functional Classification.
Prior to this, Edwards' treatment technology for heart failure was limited, and Edwards mainly focused on the valve field. This acquisitionEndotronixEdwards to Expand Heart Failure Treatment Technology, Preparing for Future Heart Failure Market
TrilogyIt is the world's first and currently the only FDA-approved TAVR (CE) for the treatment of severe symptomatic aortic regurgitation or aortic stenosis via the femoral artery.TrilogyComposed of a valve and delivery system, the implantation can be completed through three steps: valve positioning, clamping occlusion, and stable release.TrilogyThe proprietary positioning device not only enables anchoring in non-calcified conditions but also ensures commissural alignment with the native valve leaflets. Additionally, its supra-annular valve design and extra-large outflow mesh design facilitate subsequent long-term hemodynamic performance and PCI intervention. The valve is made from porcine pericardial leaflets, and the inflow end features a 24-high-density mesh design to provide annular compliance and effective sealing.The outer diameter of the delivery system is equivalent to 18F, enabling intraoperative bending adjustment and rotational positioning functions.
CordellaMainBy Cordella Sensor andComposition of the extracorporeal management platform.Among whichCordellaThe sensor is a small device about the size of a paperclip, which is injected into the pulmonary artery through its proprietary delivery system. The device can detect increases in pulmonary artery pressure values, serving as an early warning sign for pulmonary fluid accumulation and impending congestive heart failure—earlier even than symptoms like shortness of breath or weight gain appear. Pulmonary artery pressure data is recorded and wirelessly transmitted from the patient’s home to the cloud, allowing doctors to view the data in real time and proactively adjust treatment plans.For the patientHeart Failure ConditionGetTo control, thereby prolonging the patient's life and improving the quality of life.
Edwards Lifesciences is a global leader in patient-centered innovations for structural heart disease, critical care, and surgical monitoring. The company is dedicated withThe Ardent Desire to Help Patients, collaborating with world-leading clinicians and researchers to address unmet healthcare needs, thereby helping them save lives and improve the quality of life.
